Skip to main content
Top
Published in: Medical Oncology 7/2014

01-07-2014 | Original Paper

URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial–mesenchymal transition-driven invasion

Authors: Wei Peng, Jun Zhang, Jie Liu

Published in: Medical Oncology | Issue 7/2014

Login to get access

Abstract

The poor prognosis and high recurrent rate of pancreatic cancer (PC) necessitates the discovery of new predictive markers of PC invasion and prognosis. In this study, we evaluated the expression pattern of up-regulated gene 11 (URG11) in a tissue microarray with 18 pairs of PC and adjacent normal tissues. It was shown that URG11 was significantly up-regulated in PC tissues. High expression levels of URG11 were detected in all PC specimens, but were rarely detected in adjacent non-tumorous tissues. In addition, high expression of URG11 was correlated to poor prognosis. Furthermore, it was discovered that URG11 was correlated to epithelial–mesenchymal transition (EMT) markers and clinical pathological parameters indicative of high PC invasion, while knockdown of URG11 significantly changed the expression pattern of EMT markers and decreased the invasion of PC cells. These findings indicate that URG11 might enhance the invasion of PC by inducing EMT and thus lead to poor PC prognosis. Thus, URG11 has the potential to be a new predictive biomarker of PC invasion and prognosis, which may help in the diagnosis and treatment of PC patients.
Literature
3.
go back to reference Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol Mech Dis. 2008. 157–88. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol Mech Dis. 2008. 157–88.
4.
go back to reference Lian ZR, Liu J, Li L, Li X, Clayton MM, Wu MC, et al. Enhanced cell survival by the hepatitis B × antigen effector, URG11, is associated with up-regulation of beta-catenin. Clin Cancer Res. 2005;11(24):9160S–1S. Lian ZR, Liu J, Li L, Li X, Clayton MM, Wu MC, et al. Enhanced cell survival by the hepatitis B × antigen effector, URG11, is associated with up-regulation of beta-catenin. Clin Cancer Res. 2005;11(24):9160S–1S.
7.
go back to reference Lian ZR, Liu J, Li L, Li XX, Clayton M, Wu MC, et al. Enhanced cell survival of Hep3B cells by the hepatitis B × antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology. 2006;43(3):415–24. doi:10.1002/hep.21053.PubMedCrossRef Lian ZR, Liu J, Li L, Li XX, Clayton M, Wu MC, et al. Enhanced cell survival of Hep3B cells by the hepatitis B × antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology. 2006;43(3):415–24. doi:10.​1002/​hep.​21053.PubMedCrossRef
9.
go back to reference Fan R, Li XH, Du WQ, Zou X, Du R, Zhao LN, et al. Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer. 2011;128(12):2980–93. doi:10.1002/ijc.25624.PubMedCrossRef Fan R, Li XH, Du WQ, Zou X, Du R, Zhao LN, et al. Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer. 2011;128(12):2980–93. doi:10.​1002/​ijc.​25624.PubMedCrossRef
11.
go back to reference He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial–mesenchymal transition. J Cell Mol Med. 2014;18(1):49–58. doi:10.1111/jcmm.12158.PubMedCrossRef He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial–mesenchymal transition. J Cell Mol Med. 2014;18(1):49–58. doi:10.​1111/​jcmm.​12158.PubMedCrossRef
12.
go back to reference Du J, Wang JW, Tan G, Cai ZG, Zhang L, Tang B, et al. Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation. Med Oncol. 2012;29(4):2814–23. doi:10.1007/s12032-012-0175-2.PubMedCrossRef Du J, Wang JW, Tan G, Cai ZG, Zhang L, Tang B, et al. Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation. Med Oncol. 2012;29(4):2814–23. doi:10.​1007/​s12032-012-0175-2.PubMedCrossRef
13.
go back to reference Lee CL, He H, Jiang YJ, Di Y, Yang F, Li J, et al. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol. 2013;30(4). doi:10.1007/s12032-013-0700-y. Lee CL, He H, Jiang YJ, Di Y, Yang F, Li J, et al. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol. 2013;30(4). doi:10.​1007/​s12032-013-0700-y.
14.
go back to reference Gunturu KS, Yao XP, Cong XY, Thumar JR, Hochster HS, Stein SM, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1). doi:10.1007/s12032-012-0361-2. Gunturu KS, Yao XP, Cong XY, Thumar JR, Hochster HS, Stein SM, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1). doi:10.​1007/​s12032-012-0361-2.
18.
go back to reference Zhao N, Sun BC, Zhao XL, Liu ZY, Sun T, Qiu ZQ, et al. Coexpression of Bcl-2 with epithelial–mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma. Med Oncol. 2012;29(4):2780–92. doi:10.1007/s12032-012-0207-y.PubMedCrossRef Zhao N, Sun BC, Zhao XL, Liu ZY, Sun T, Qiu ZQ, et al. Coexpression of Bcl-2 with epithelial–mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma. Med Oncol. 2012;29(4):2780–92. doi:10.​1007/​s12032-012-0207-y.PubMedCrossRef
Metadata
Title
URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial–mesenchymal transition-driven invasion
Authors
Wei Peng
Jun Zhang
Jie Liu
Publication date
01-07-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 7/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0064-y

Other articles of this Issue 7/2014

Medical Oncology 7/2014 Go to the issue